Polivy combo's swift approval adds new lymphoma option

11 June 2019

Shares in Roche (ROG: SIX) were 2% higher by lunchtime on Tuesday following the US Food and Drug Administration (FDA) approval of the first chemo-immunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The combination approved was Polivy (polatuzumab vedotin-piiq), an antibody-drug conjugate (ADC) that specifically targets CD79b, a protein expressed in the majority of B-cells, plus bendamustine and another Roche drug, MabThera/Rituxan (rituximab).

Patients who have received at least two prior therapies will be considered for treatment. DLBCL is the most common type of non-Hodgkin lymphoma (NHL).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK